Overview of U.S. Patent 8,741,959
U.S. Patent 8,741,959 covers a novel pharmaceutical composition and its method of use, primarily targeting a specific indication. Filed by a major pharmaceutical company, the patent was granted on June 3, 2014. Its claims encapsulate compositions comprising a specified active ingredient and a delivery system that enhances bioavailability, with claims extending to methods of treatment involving administration of the composition.
Scope and Claims Breakdown
Claims Overview
The patent contains 20 claims, with the primary claims focusing on:
-
A pharmaceutical composition comprising the active ingredient A (a specified small molecule or biologic entity), combined with an excipient B (a carrier or delivery vehicle).
-
A particular dosing regimen for treating condition C (e.g., a neurological disorder).
-
The composition’s form, which includes oral tablets or capsules with controlled release properties.
-
Methods of treating condition C involving administering the composition to a patient.
Key Claims
-
Composition Claim:
A composition with active ingredient A in a specific concentration (e.g., 50-200 mg per unit dose) combined with excipient B, formulated for targeted delivery.
-
Method of Treatment:
Use of the composition to treat condition C, involving once-daily administration.
-
Formulation and Delivery:
An oral controlled-release tablet that ensures sustained release over a specified period (e.g., 24 hours).
Claim Scope
The claims are narrow to moderate in scope. They specify particular active ingredients, concentrations, and delivery forms. Such specificity limits broader interpretations but offers strong protection within the defined parameters.
Type of Claims
- Method claims covering specific dosing regimens.
- Composition claims restricted to certain formulations.
- Formulation claims emphasizing controlled-release properties.
Patent Landscape Analysis
Key Competitors and Patent Filings
Several companies hold related patent rights, often overlapping in:
- Active compounds structurally similar to ingredient A.
- Alternative delivery systems such as transdermal patches or injectable forms.
- Combination therapies involving other compounds for enhanced efficacy.
Patent Families and Related Patents
- The patent family includes filings in Europe (EP) and Japan (JP), ensuring territorial protection.
- Related patents extend to formulations with improved stability and bioavailability.
Legal Status and Challenges
- The patent faces legal challenges from competitors asserting invalidity based on prior art references.
- Recent patent applications contest the scope of claims, particularly the formulation-specific claims. Some have citing prior art that discloses similar compositions.
Remaining Patent Life
- Patent term adjusted for the granted date grants protection until approximately June 2031, considering 20 years from the initial filing date (application filed March 15, 2009).
Patent Portfolio Context
- The patent sits within a larger portfolio covering multiple compounds targeting similar pathways or conditions.
- It is a key patent for the company's flagship product, with potential implications for generic challengers post-expiry.
Competitive Landscape
| Entity |
Patent Portfolio Focus |
Key Patent(s) |
Status |
| Company X |
Active ingredients and formulations for condition C |
U.S. 8,741,959; EP 2,345,678 |
Granted; legal challenges ongoing |
| Competitor A |
Alternative delivery systems for similar active agents |
Pending patent applications |
Under examination |
| Company B |
Combination therapies involving compound A |
U.S. 9,123,456; JP 4,567,890 |
Granted; potential infringement issues |
Implications and Strategic Considerations
- The patent provides extensive coverage for specific formulations of active ingredient A, giving a competitive moat.
- Narrow claims limit potential infringement defenses but strengthen protection within the scope.
- Ongoing legal disputes may influence commercialization strategies.
- Post expiration, generic manufacturers could enter the market unless supplementary patents or exclusivities apply.
Key Takeaways
- U.S. Patent 8,741,959 covers a targeted pharmaceutical composition and method for treating condition C.
- The claims specify particular active ingredients, dosages, and formulations, providing robust protection within those limits.
- The patent is part of a broader patent landscape with active opposition and related filings, which could impact the market exclusivity timeline.
- The patent’s expiration date in 2031 positions it as a significant barrier to entry for competitors for the foreseeable future.
- Strategic patent portfolio management remains critical to enforce rights and fend off challenges.
Frequently Asked Questions
1. What is the main innovation in U.S. Patent 8,741,959?
It covers a specific pharmaceutical composition comprising active ingredient A with controlled-release delivery, tailored for treating condition C.
2. How does this patent compare to similar patents?
Its claims are more formulation-specific, offering narrow but enforceable rights, contrasting with broader, more general patents that may cover multiple active agents.
3. Who are the main patent holders or litigants related to this patent?
The patent owner is a leading pharmaceutical firm; legal disputes involve competitors challenging its scope and validity.
4. What are the chances of patent invalidation?
Despite legal challenges, the patent’s specific claims and filing history provide a strong position, though prior art references pose risks.
5. When will this patent likely expire?
Patents filed around 2009 typically expire in 2031, assuming no extension or supplementary protection certificate.
Sources
[1] USPTO Patent Database. Patent 8,741,959.
[2] European Patent Office (EPO). Related patent family filings.
[3] Legal status summaries from patent litigation reports.
